Page 3 - Toby Maher News Today

/PRNewswire/ -- The worlds first-in-class candidate substance against idiopathic pulmonary fibrosis, Bersiposocin (DWN12088), which is under development...

A clinical trial found that rituximab and cyclophosphamide had similar outcomes for interstitial lung disease associated with connective tissue disorders.

Drug targeting B cells as effective as broad-spectrum immunosuppressant in lung disease

/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),...

The new results show stabilization of disease already from week 6 and confirm the unprecedented increase in lung function over timeVicore will accelerate clinical developmentInvitation to conference

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, in idiopat...

LYT-100 was well-tolerated compared to pirfenidone in a healthy older adult crossover trial, informing dose selection for recently initiated trial in IPF PureTech Health plc (Nasdaq: PRTC, LSE:

Investegate announcements from PureTech Health PLC, PRTC LYT-100 Data & IPF Trial Design at ERS Conf

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral...

GOTHENBURG, Sweden, Aug. 19, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a...